Carcinoma, Squamous Cell of Head and Neck Clinical Trial
Official title:
An Open-label, Single Arm, Phase II Trial to Investigate the Safety and Efficacy of Sym004 in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Who Have Failed Anti-EGFR Monoclonal Antibody-based Therapy
The trial is designed as a multi-center, open label Phase 2 trial that investigates the
efficacy and safety of Sym004 in subjects with squamous cell cancer of the head and neck
(SCCHN). Subjects included must have responded to previous anti-epidermal growth factor
receptor (anti-EGFR) monoclonal antibody-based therapy and subsequently become resistant to
that therapy. It is believed that Sym004 has the potential to induce tumor responses and
provide a superior treatment option to subjects with advanced SCCHN.
Symphogen was the sponsor for planning/conducting and reporting results for this trial.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02113878 -
Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck
|
Phase 1 | |
| Active, not recruiting |
NCT03291002 -
Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC
|
Phase 1 | |
| Terminated |
NCT02277184 -
Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma
|
Phase 1 | |
| Completed |
NCT01080066 -
A Post Marketing Surveillance Study of Cetuximab in Patients With Squamous Cell Carcinoma of Head and Neck (SCCHN)
|
N/A | |
| Completed |
NCT02585973 -
Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC
|
Phase 1 | |
| Completed |
NCT01836029 -
Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
|
Phase 2 | |
| Active, not recruiting |
NCT03715946 -
Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03088059 -
Biomarker-based Study in R/M SCCHN
|
Phase 2 | |
| Recruiting |
NCT06003231 -
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
|
Phase 2 | |
| Terminated |
NCT02438995 -
Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck
|
Phase 1 | |
| Completed |
NCT02242916 -
State of the Art Photon Therapy Versus Particle Therapy for Recurrent Head & Neck Tumors; a Planning Study
|
N/A | |
| Recruiting |
NCT01876693 -
A Prospective Study of Prophylactic Gastrostomy in Head and Neck Cancer Patients Undergoing Chemoradiotherapy
|
N/A | |
| Terminated |
NCT02655068 -
Phase III Trial of PET/CT vs. CTSurveilance for Head and Neck Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT03509012 -
Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT02296684 -
Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT03799744 -
Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma
|
Phase 1 | |
| Completed |
NCT03109158 -
NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03485209 -
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
|
Phase 2 | |
| Completed |
NCT01307267 -
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
|
Phase 1 | |
| Terminated |
NCT02822482 -
Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss
|
Phase 1/Phase 2 |